Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria

NCT01594931 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.

NCT NCT01594931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01594931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria
Lead sponsor
Medicines for Malaria Venture
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
April 30, 2006
Enrollment
477 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

plasmodium falciparum malaria